Dublin, Jan. 07, 2026 (GLOBE NEWSWIRE) — The “In Situ Hybridization Market Report by Product, Technique, Application, End User, Countries and Company Analysis 2025-2033” has been added to ResearchAndMarkets.com’s offering.
The In Situ Hybridization (ISH) Market is expected to grow to US$ 3.22 billion in 2033 from US$ 1.73 billion in 2024, expanding at a CAGR of 7.14% from 2025 to 2033. Market expansion is fueled by rising use of ISH in cancer diagnosis, infectious diseases research, and gene research, as well as technological advancements improving precision and efficiency in molecular and cellular inspection.
Growth Drivers in the In Situ Hybridization Market
Emerging Cancer and Genetic Disorders Prevalence
Emerging prevalence of cancer and genetic disorders is one of the key drivers of the growth in the ISH market. Diagnostics of cancer usually depend on ISH methods such as fluorescence in situ hybridization (FISH) to identify chromosomal changes and detect tumor markers. Screening for genetic disorders also utilizes ISH to identify specific mutations in DNA or RNA molecules, aiding in early detection and specific treatment. This increasing disease burden worldwide stimulates the need for ISH-based diagnostic products. In 2022, nearly 20 million new cases of cancer (including NMSC) and 9.7 million cancer deaths (including NMSC) occurred. The estimates indicate that one in five men or women ever get cancer, while one in nine men and one in 12 women die of cancer.
Advances in Molecular Diagnostic Technologies
Technological advancements in ISH, such as automated devices, high-resolution imaging, and multiplex assays, have enhanced diagnostic efficacy and efficiency. Applications such as chromogenic ISH and RNA ISH are gaining greater implementation in pathology laboratories and research institutions. Incorporating digital imaging further facilitates visualization and analysis, hastening the implementation of ISH in clinical and research settings. August 2024 – Paragonix Technologies has enlarged its GUARDIAN Registry by adding a new sub-study dedicated to cardiac research. This effort is designed to expand knowledge of rejection after transplant, with a focus on molecular diagnostics. For the first time ever, this broad-scale data set connects important pre, peri, and post-transplant data, such as donor organ data, preservation data, post-operative results, survival rates, and post-transplant rejection data.
Increasing Research Grants and Precision Medicine Programs
Government and private grants for molecular biology research and precision medicine programs are driving ISH adoption. Precision medicine is dependent on knowing genetic differences at a cell level, and ISH is used to find biomarkers for targeted treatments. Investments in oncology and infectious disease research are fueling market growth. March 5, 2025 – Genome Canada launched today the Canadian Precision Health Initiative (CPHI) with Government of Canada investment of $81 million. Total investment of $200 million, with co-funding from public sector partners, academia, and industry partners, is anticipated.
Challenges in the In Situ Hybridization Market
High Cost and Technical Complexity
ISH assays need dedicated reagents, expensive imaging equipment, and trained technicians, and therefore are too expensive for small clinics and health centers. The intricate sample processing and extended turnaround time further hinder adoption in low-resource areas, which is a challenge for market penetration in developing economies.
Limited Awareness in Developing Markets
Although it has advantages, knowledge of ISH methods is still low in developing regions. Most diagnostic facilities continue to use traditional techniques because of a lack of training and infrastructure. This lack of knowledge, combined with a dearth of trained personnel, retards the uptake of innovative ISH solutions outside large research and clinical centers.
In Situ Hybridization Analytical Instruments Market
The ISH analytical instruments market comprises automated platforms, microscopes, and imaging systems used to carry out high-accuracy hybridization and visualization. The instruments enhance efficiency, minimize human error, and enable multiplex analysis for diagnostics and research. Demand from oncology research centers and hospitals fuels the sector, with increasing adoption of automated systems that allow greater throughput in clinical and academic applications.
Fluorescence In Situ Hybridization (FISH) Market
The FISH market is a critical portion of ISH, commonly employed to identify chromosomal aberrations and gene mutations. Its high sensitivity and capacity for visualizing genetic information in real time make it a central component in cancer diagnosis, prenatal testing, and infectious disease research. FISH adoption is growing worldwide because of its application in precision oncology, wherein accurate genetic characterization is paramount for targeted treatments.
In Situ Sequencing Market
The in situ sequencing (ISS) market entails sophisticated methods to sequence nucleic acids directly within cells or tissues. This technique offers spatial transcriptomics, allowing scientists to visualize gene expression at cellular resolution. It is increasingly being used in cancer biology, neuroscience, and infectious disease research, as it offers profound insights into cellular heterogeneity and tissue microenvironments without compromising on spatial context.
Cancer Diagnostics & Research In Situ Hybridization Market
ISH cancer diagnostic and research cancer market is expanding swiftly on account of increasing cancer incidence globally. ISH allows for the early detection of tumors, identification of biomarkers, and monitoring of response to therapy. ISH is applied in research institutes to investigate oncogenes and chromosomal translocations. Strong expansion in this segment of the market is stimulated by the increased application of RNA ISH and FISH in pathology laboratories for targeted cancer therapy choice.
In Situ Hybridization Diagnostic Laboratories Market
Diagnostic labs are a key end-user of the product because ISH plays an important role in clinical diagnostics, pathology, and genetics. Labs use ISH for diagnosing cancer by biopsy analysis, prenatal screening, and detecting infectious diseases. The increasing availability of automated hybridization platforms and partnerships between laboratories and hospitals for advanced molecular diagnostics boost growth.
Key Attributes
| Report Attribute | Details |
| No. of Pages | 200 |
| Forecast Period | 2024-2033 |
| Estimated Market Value (USD) in 2024 | $1.73 Billion |
| Forecasted Market Value (USD) by 2033 | $3.22 Billion |
| Compound Annual Growth Rate | 7.1% |
| Regions Covered | Global |
Key Topics Covered
1. Introduction
2. Research & Methodology
3. Executive Summary
4. Market Dynamics
4.1 Growth Drivers
4.2 Challenges
5. Global In Situ Hybridization Market
5.1 Historical Market Trends
5.2 Market Forecast
6. Market Share Analysis
6.1 By Product
6.2 By Technique
6.3 By Application
6.4 By End User
6.5 By Countries
7. Product
7.1 Analytical Instruments
7.2 Probes, Kits & Reagents
7.3 Software & Services
7.4 Other Products
8. Technique
8.1 Fluorescence ISH (FISH)
8.2 Chromogenic ISH (CISH)
8.3 Amplified RNA-ISH (HCR, RNAscope)
8.4 In-situ Sequencing (ISS)
9. Application
9.1 Cancer Diagnostics & Research
9.2 Infectious Diseases
9.3 Genetic & Rare Disorders
9.4 Neurological & Developmental Biology
9.5 Other Applications
10. End User
10.1 Diagnostic Laboratories
10.2 Academic & Research Institutes
10.3 Pharma-Biotech & CROs
10.4 Veterinary & Environmental Labs
11. Countries
11.1 North America
11.2 Europe
11.3 Asia Pacific
11.4 Latin America
11.5 Middle East & Africa
12. Value Chain Analysis
13. Porter’s Five Forces Analysis
13.1 Bargaining Power of Buyers
13.2 Bargaining Power of Suppliers
13.3 Degree of Competition
13.4 Threat of New Entrants
13.5 Threat of Substitutes
14. SWOT Analysis
14.1 Strength
14.2 Weakness
14.3 Opportunity
14.4 Threats
15. Pricing Benchmark Analysis
16. Key Players Analysis
16.1 PerkinElmer, Inc.
16.2 Thermo Fisher Scientific, Inc.
16.3 BioView
16.4 Agilent Technologies, Inc.
16.5 Merck KGaA
16.6 Bio-Rad Laboratories, Inc.
16.7 Oxford Gene Technology IP Limited
16.8 Neogenomics Laboratories, Inc.
16.9 Advanced Cell Diagnostics, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/tk6tqi
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- In Situ Hybridization Market
